GSK’s Oncology Expansion Heavily Dependent On Dabrafenib, Trametinib
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline announced NDA filings for BRAF inhibitor dabrafenib and MEK inhibitor trametinib in metastatic melanoma on Aug. 3. The two compounds represent one-quarter of the company’s novel oncology agents in clinical development, according to the most recent pipeline update.